Ó³»´«Ã½ core member and gene editing pioneer David Liu describes a framework that could enable the treatment of 1,000 patients with personalized gene editing therapies by 2030.
A single-letter edit in DNA reduces levels of the disease-causing prion protein in the brain and could lead to a preventative, one-time treatment for the deadly neurodegenerative disorder.
The new system is the first to use a DNA-mobilizing enzyme called a CRISPR-associated transposase to make targeted gene-sized edits at therapeutically useful levels in human cells.
Ó³»´«Ã½ scientists built a diverse library of compounds and found one that stabilizes a dysfunctional protein in Crohn’s disease, demonstrating their library’s potential to uncover new therapeutic strategies.
Researchers find four coordinated gene expression programs in immune cells from glioma tumors, including two that could lead to immunotherapy resistance.
Myocarditis is driven by a different immune response than the anti-tumor one, suggesting that the serious complication could one day be managed without halting cancer therapy.
Researchers double the number of genetic factors associated with this common arrhythmia, highlighting biological pathways that could be targeted by new medicines.
Ó³»´«Ã½ and Denmark-based scientists are collaborating to scale up their efforts to turn genetic insights into the fundamental biological mechanisms underlying metabolic disease.
The Novo Nordisk Foundation Center for Genomic Mechanisms of Disease is forging connections between Danish and Ó³»´«Ã½ scientists. Here are two of their stories.
The Novo Nordisk Foundation Center for Genomic Mechanisms of Disease brings together Danish and Ó³»´«Ã½ scientists. Managing director Kasper Lage shares the center’s origin story, its achievements so far, and what the future holds.
Ralda Nehme, director of Ó³»´«Ã½â€™s stem cell program, talks about how stem cells can be a model for disease in a dish and what scientists can learn from these experiments.
A low-cost CRISPR-based paper strip test distinguishes between influenza types and can be reprogrammed to recognize different viruses including the H5N1 bird flu virus.
Scientists from the US and West Africa have teamed up to build a better public health network that can quickly detect and respond to emerging viral threats.
In a pilot study with patient samples, the technology performed as well as the current gold-standard methods, yielding accurate results within hours instead of days.
After living with angiosarcoma for decades, Jim Chapdelaine found support in an online community of patients and contributed to research that’s now shedding light on the roots of his own illness